Table of Contents

1 Study Coverage

• 1.1 Hyperimmune Globulins Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Hyperimmune Globulins Market Size Growth Rate by Product
  • 1.4.2 Hepatitis B Immunoglobulins
  • 1.4.3 Rabies Immunoglobulins
  • 1.4.4 Tetanus Immunoglobulins
  • 1.4.5 Rho(D) Immunoglobulins
  • 1.4.6 Others
• 1.5 Market by End User
  • 1.5.1 Global Hyperimmune Globulins Market Size Growth Rate by End User
  • 1.5.2 Government Institutions
  • 1.5.3 Private Sector
  • 1.5.4 Other
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Hyperimmune Globulins Market Size
  • 2.1.1 Global Hyperimmune Globulins Revenue 2014-2025
  • 2.1.2 Global Hyperimmune Globulins Sales 2014-2025
• 2.2 Hyperimmune Globulins Growth Rate by Regions
  • 2.2.1 Global Hyperimmune Globulins Sales by Regions
  • 2.2.2 Global Hyperimmune Globulins Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Hyperimmune Globulins Sales by Manufacturers
  • 3.1.1 Hyperimmune Globulins Sales by Manufacturers
  • 3.1.2 Hyperimmune Globulins Sales Market Share by Manufacturers
  • 3.1.3 Global Hyperimmune Globulins Market Concentration Ratio (CR5 and HHI)
• 3.2 Hyperimmune Globulins Revenue by Manufacturers
  • 3.2.1 Hyperimmune Globulins Revenue by Manufacturers (2014-2019)
  • 3.2.2 Hyperimmune Globulins Revenue Share by Manufacturers (2014-2019)
• 3.3 Hyperimmune Globulins Price by Manufacturers
• 3.4 Hyperimmune Globulins Manufacturing Base Distribution, Product Types
  • 3.4.1 Hyperimmune Globulins Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Hyperimmune Globulins Product Type
  • 3.4.3 Date of International Manufacturers Enter into Hyperimmune Globulins Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Hyperimmune Globulins Sales by Product
• 4.2 Global Hyperimmune Globulins Revenue by Product
• 4.3 Hyperimmune Globulins Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Hyperimmune Globulins Breakdown Data by End User

6 North America

• 6.1 North America Hyperimmune Globulins by Countries
  • 6.1.1 North America Hyperimmune Globulins Sales by Countries
  • 6.1.2 North America Hyperimmune Globulins Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Hyperimmune Globulins by Product
• 6.3 North America Hyperimmune Globulins by End User

7 Europe

• 7.1 Europe Hyperimmune Globulins by Countries
  • 7.1.1 Europe Hyperimmune Globulins Sales by Countries
  • 7.1.2 Europe Hyperimmune Globulins Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Hyperimmune Globulins by Product
• 7.3 Europe Hyperimmune Globulins by End User

8 Asia Pacific

• 8.1 Asia Pacific Hyperimmune Globulins by Countries
  • 8.1.1 Asia Pacific Hyperimmune Globulins Sales by Countries
  • 8.1.2 Asia Pacific Hyperimmune Globulins Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Hyperimmune Globulins by Product
• 8.3 Asia Pacific Hyperimmune Globulins by End User

9 Central & South America

• 9.1 Central & South America Hyperimmune Globulins by Countries
  • 9.1.1 Central & South America Hyperimmune Globulins Sales by Countries
  • 9.1.2 Central & South America Hyperimmune Globulins Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Hyperimmune Globulins by Product
• 9.3 Central & South America Hyperimmune Globulins by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Hyperimmune Globulins by Countries
  • 10.1.1 Middle East and Africa Hyperimmune Globulins Sales by Countries
  • 10.1.2 Middle East and Africa Hyperimmune Globulins Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Hyperimmune Globulins by Product
• 10.3 Middle East and Africa Hyperimmune Globulins by End User

11 Company Profiles

• 11.1 CSL Behring
  • 11.1.1 CSL Behring Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 CSL Behring Hyperimmune Globulins Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 CSL Behring Hyperimmune Globulins Products Offered
  • 11.1.5 CSL Behring Recent Development
• 11.2 Grifols
  • 11.2.1 Grifols Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Grifols Hyperimmune Globulins Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Grifols Hyperimmune Globulins Products Offered
  • 11.2.5 Grifols Recent Development
• 11.3 Biotest
  • 11.3.1 Biotest Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Biotest Hyperimmune Globulins Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Biotest Hyperimmune Globulins Products Offered
  • 11.3.5 Biotest Recent Development
• 11.4 Kedrion
  • 11.4.1 Kedrion Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Kedrion Hyperimmune Globulins Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Kedrion Hyperimmune Globulins Products Offered
  • 11.4.5 Kedrion Recent Development
• 11.5 CBPO
  • 11.5.1 CBPO Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 CBPO Hyperimmune Globulins Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 CBPO Hyperimmune Globulins Products Offered
  • 11.5.5 CBPO Recent Development
• 11.6 Emergent (Cangene)
  • 11.6.1 Emergent (Cangene) Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Emergent (Cangene) Hyperimmune Globulins Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Emergent (Cangene) Hyperimmune Globulins Products Offered
  • 11.6.5 Emergent (Cangene) Recent Development
• 11.7 Kamada
  • 11.7.1 Kamada Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Kamada Hyperimmune Globulins Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Kamada Hyperimmune Globulins Products Offered
  • 11.7.5 Kamada Recent Development
• 11.8 CNBG
  • 11.8.1 CNBG Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 CNBG Hyperimmune Globulins Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 CNBG Hyperimmune Globulins Products Offered
  • 11.8.5 CNBG Recent Development
• 11.9 Hualan Bio
  • 11.9.1 Hualan Bio Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Hualan Bio Hyperimmune Globulins Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Hualan Bio Hyperimmune Globulins Products Offered
  • 11.9.5 Hualan Bio Recent Development
• 11.10 Shanghai RAAS
  • 11.10.1 Shanghai RAAS Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Shanghai RAAS Hyperimmune Globulins Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Shanghai RAAS Hyperimmune Globulins Products Offered
  • 11.10.5 Shanghai RAAS Recent Development
• 11.11 Sichuan Yuanda Shuyang
• 11.12 ADMA Biologics

12 Future Forecast

• 12.1 Hyperimmune Globulins Market Forecast by Regions
  • 12.1.1 Global Hyperimmune Globulins Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Hyperimmune Globulins Revenue Forecast by Regions 2019-2025
• 12.2 Hyperimmune Globulins Market Forecast by Product
  • 12.2.1 Global Hyperimmune Globulins Sales Forecast by Product 2019-2025
  • 12.2.2 Global Hyperimmune Globulins Revenue Forecast by Product 2019-2025
• 12.3 Hyperimmune Globulins Market Forecast by End User
• 12.4 North America Hyperimmune Globulins Forecast
• 12.5 Europe Hyperimmune Globulins Forecast
• 12.6 Asia Pacific Hyperimmune Globulins Forecast
• 12.7 Central & South America Hyperimmune Globulins Forecast
• 12.8 Middle East and Africa Hyperimmune Globulins Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Hyperimmune Globulins Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

Hyperimmune globulin is similar to intravenous immunoglobulin (IVIG) except that it is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. This is in contrast to vaccines that provide "active" immunity. However, vaccines take much longer to achieve that purpose while hyperimmune globulin provides instant "passive" short-lived immunity. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
Hyperimmune globulin is prepared from the plasma of donors with high titers of antibody against a specific organism or antigen. Some agents against which hyperimmune globulins are available include hepatitis B, rabies, tetanus toxin, varicella-zoster, etc. Administration of hyperimmune globulin provides "passive" immunity to the patient against an agent. Hyperimmune globulin may have serious side effects, thus usage is taken very seriously.
The global Hyperimmune Globulins market is valued at 82 million US$ in 2018 and will reach 180 million US$ by the end of 2025, growing at a CAGR of 11.5% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Hyperimmune Globulins market based on company, product type, end user and key regions.

This report studies the global market size of Hyperimmune Globulins in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Hyperimmune Globulins in these regions.
This research report categorizes the global Hyperimmune Globulins market by top players/brands, region, type and end user. This report also studies the global Hyperimmune Globulins market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
CSL Behring
Grifols
Biotest
Kedrion
CBPO
Emergent (Cangene)
Kamada
CNBG
Hualan Bio
Shanghai RAAS
Sichuan Yuanda Shuyang
ADMA Biologics

Market size by Product
Hepatitis B Immunoglobulins
Rabies Immunoglobulins
Tetanus Immunoglobulins
Rho(D) Immunoglobulins
Others
Market size by End User
Government Institutions
Private Sector
Other

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Hyperimmune Globulins market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Hyperimmune Globulins market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Hyperimmune Globulins companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Hyperimmune Globulins submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Hyperimmune Globulins are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Hyperimmune Globulins market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.